Assignee
INTRABIO LTD
GB·15 granted patents·11 pending applications·21 citations·filing 2017–2025
Top patents by PatentIndex Score
26 records- 0193US11998518B2Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionINTRABIO LTD·Filed 2020·Granted Jun 4, 2024·3 cites·11 claims
- 0292US11690830B2Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subjectINTRABIO LTD·Filed 2021·Granted Jul 4, 2023·2 cites·20 claims
- 0391US11400067B2Pharmaceutical compositions and uses directed to lysosomal storage disordersINTRABIO LTD·Filed 2017·Granted Aug 2, 2022·4 cites·34 claims
- 0490US11083718B2Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subjectINTRABIO LTD·Filed 2018·Granted Aug 10, 2021·3 cites·20 claims
- 0585US10905670B2Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionINTRABIO LTD·Filed 2017·Granted Feb 2, 2021·5 cites·9 claims
- 0684US2026027077A1Pharmaceutical compositions and uses directed to lysosomal storage disordersINTRABIO LTD·Filed 2025·Application pending·0 cites
- 0783US12433863B2Pharmaceutical compositions and uses directed to lysosomal storage disordersINTRABIO LTD·Filed 2024·Granted Oct 7, 2025·0 cites·27 claims
- 0882US12329733B2Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionINTRABIO LTD·Filed 2023·Granted Jun 17, 2025·0 cites·10 claims
- 0981US12121513B2Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subjectINTRABIO LTD·Filed 2023·Granted Oct 22, 2024·0 cites·21 claims
- 1079US12433862B2Pharmaceutical compositions and uses directed to lysosomal storage disordersINTRABIO LTD·Filed 2022·Granted Oct 7, 2025·0 cites·20 claims
- 1177US11793782B2Therapeutic agents for neurodegenerative diseasesINTRABIO LTD·Filed 2018·Granted Oct 24, 2023·1 cites·22 claims
- 1277US11471434B2Treatment for migraineINTRABIO LTD·Filed 2018·Granted Oct 18, 2022·2 cites·20 claims
- 1377US2025332133A1Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionINTRABIO LTD·Filed 2025·Application pending·0 cites
- 1476US2024189267A1Therapeutic agents for neurodegenerative diseasesINTRABIO LTD·Filed 2024·Application pending·0 cites
- 1574US2023210799A1Therapeutic agents for neurodegenerative diseasesINTRABIO LTD·Filed 2023·Application pending·0 cites
- 1671US2026069562A1Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disordersINTRABIO LTD·Filed 2025·Application pending·0 cites
- 1766US12145899B2Deuterated analogs of acetyl-leucineINTRABIO LTD·Filed 2019·Granted Nov 19, 2024·1 cites·20 claims
- 1858US12144792B2Therapeutic agents for neurodegenerative diseasesINTRABIO LTD·Filed 2017·Granted Nov 19, 2024·0 cites·18 claims
- 1955US2024208895A1Branched-chain amino acid derivatives to treat diseaseINTRABIO LTD·Filed 2023·Application pending·0 cites
- 2055US2023201150A1The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxiaINTRABIO LTD·Filed 2021·Application pending·0 cites
- 2154US2023051742A1Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriersINTRABIO LTD·Filed 2021·Application pending·0 cites
- 2252US2025129011A1Deuterated analogs of acetyl-leucineINTRABIO LTD·Filed 2024·Application pending·0 cites
- 2351US11660279B2Therapeutic agents for treating restless leg syndromeINTRABIO LTD·Filed 2019·Granted May 30, 2023·0 cites·18 claims
- 2450US2022362189A1Combination therapy with acetyl-leucine and miglustatINTRABIO LTD·Filed 2020·Application pending·0 cites
- 2549US12458614B2Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disordersINTRABIO LTD·Filed 2018·Granted Nov 4, 2025·0 cites·13 claims
- 2642US2022142959A1Leucine, acetyl leucine, and related analogs for treating diseaseINTRABIO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when INTRABIO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →